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Abstract
Objective: CD5 plays a crucial role in autoimmunity and is a well-established genetic risk factor of developing RA. Recently,
evidence of positive selection has been provided for the CD5 Pro224-Val471 haplotype in East Asian populations. The aim of
the present work was to further analyze the functional relevance of non-synonymous CD5 polymorphisms conforming the
ancestral and the newly derived haplotypes (Pro224-Ala471 and Pro224-Val471, respectively) as well as to investigate the
potential role of CD5 on the development of SLE and/or SLE nephritis.
Methods: The CD5 SNPs rs2241002 (C/T; Pro224Leu) and rs2229177 (C/T; Ala471Val) were genotyped using TaqMan allelic
discrimination assays in a total of 1,324 controls and 681 SLE patients of Spanish origin. In vitro analysis of CD3-mediated T
cell proliferative and cytokine response profiles of healthy volunteers homozygous for the above mentioned CD5
haplotypes were also analyzed.
Results: T-cell proliferation and cytokine release were significantly increased showing a bias towards to a Th2 profile after
CD3 cross-linking of peripheral mononuclear cells from healthy individuals homozygous for the ancestral Pro224-Ala471
(CC) haplotype, compared to the more recently derived Pro224-Val471 (CT). The same allelic combination was statistically
associated with Lupus nephritis.
Conclusion: The ancestral Ala471 CD5 allele confers lymphocyte hyper-responsiveness to TCR/CD3 cross-linking and is
associated with nephritis in SLE patients.
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Introduction
Systemic lupus erythematosus (SLE) is a systemic chronic
complex autoimmune disease characterized by hyperactive T and
B cells, auto-antibody production and immune complex deposi-
tion. It is considered to be the result of loss of self-tolerance
triggered by certain environmental factors in genetically suscep-
tible individuals [1]. Genetic predisposition commonly results from
the combined effect of variants of a large number or genes, each
allele contributing only mildly (odds ratio ,1.5). During the past
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decade, the understanding of the genetic basis of SLE has been
enormously expanded mainly due to genome wide association
studies (GWAS). Although the loci identified in these studies as
SLE genetic risk factors still account for only about 15% of the
heritability of the disease [2–4], many have important roles in the
control of innate (e.g., complement components, and interferon-
inducible genes) and adaptive (e.g., major histocompatibility
complex, and lymphocyte signalling effectors) immune responses
[4]. Interestingly, some of these genetic factors contribute
specifically to the clinical manifestations of SLE, leading to earlier
onset and more severe forms of SLE [5,6].
Extensive studies have highlighted the existence of aberrant
lymphocyte function in SLE patients [7]. This may result in part
from deficient control of antigen receptor-mediated signalling by
regulatory molecules involved in the normal homeostasis of
immune responses and/or the maintenance of self-tolerance
(e.g., PD-1, CTLA-4, FccRIIB or CD22). One of such molecules
is CD5, a lymphocyte surface receptor constitutively expressed by
all T cells and the B1a subset of mature B cells that has been
involved in the production of low-affinity polyreactive antibodies
[8] and is found expanded in patients undergoing autoimmune
disorders such as rheumatoid arthritis (RA) [9], SLE [10], Sjo¨gren
syndrome (SS) [11], Grave’s Basedow thyroiditis [12], and type I
Diabetes Mellitus [13]. Although initially considered as a co-
stimulatory molecule, the role of CD5 as a negative regulator of
signalling by the antigen-specific receptor was deduced from
hyper-responsiveness of thymocytes and peritoneal B1a cells from
CD5-deficient mice (CD52/2) to antigen-specific receptor cross-
linking [14,15]. Later work with transgenic mice expressing high-
or low-affinity T-cell receptors (TCR), further indicated that CD5
expression is developmentally regulated by TCR avidity and that
CD5 has a role in the fine tuning of TCR signalling [16,17].
Notwithstanding, recent studies have revealed, a broader role of
CD5 in lymphocyte biology that include regulation of activation-
induced T cell death [18,19] and recognition of pathogen-
associated molecular patterns [20]. The key regulatory role played
by CD5 is also supported by its physical association to the antigen-
specific receptor [21,22], as well as by its co-localization with the
TCR/CD3 at the central area of the mature immune synapse,
where it lowers the T cell response elicited by antigen presentation
[23]. The molecular basis for the CD5-mediated negative
signalling still remains unsolved, but independent studies have
implicated different negative signalling effectors such as Src
homology 2 domain-containing phosphatase 1 (SHP-1/PTPN6)
[24], Ras GTPase activating protein (Ras-GAP) [25], cell Casitas
B-lineage Lymphoma (c-CBL) [26,27] and Casein Kinase 2 (CK2)
[28]. In fact, CD5 possesses a long cytoplasmic tail devoid of
intrinsic enzymatic activity but well equipped with a number of
consensus motifs available to phosphorylation and/or interaction
with cytoskeletal and signalling proteins [29,30].
Consistent with its regulatory role, CD5 surface expression is
found up-regulated on lymphocyte subsets with regulatory/
suppressor function, namely regulatory T cells (Treg) [31] and
regulatory B cells (Breg) [32], as well as on lymphocytes anergized
via repeated stimulation by endogenous or exogenous antigens
[33,34].
In humans, no CD5-deficiency has been reported so far.
However, a recent study has shown that an AlaRVal substitution
(rs2229177, C/T) at amino acid 471 (Ala471Val), just C-terminal
to an ITAM-like cytoplasmic motif, is relevant to CD5-mediated
signal transduction [35]. Thus, the ancestral Ala471 variant was
less efficient than the more recently derived Val471 allele in
providing early biochemical signals. Interestingly, the derived
allele of rs2229177*T (Val471), together with the ancestral allele
(rs2241002*C, Pro224) of a second and also highly frequent
nonsynonymous single nucleotide polymorphism (SNP)
(rs2241002, C/T; Pro224Leu), located in the extracellular region
of the CD5 molecule, was found to conform a haplotype that has
been positively selected in East Asian populations [35]. This
indicates the possible targeting of CD5 polymorphisms by putative
environmental factors during recent human evolution. The
present work further extends the analysis of CD5 rs2229177 and
rs2241002 functional genetic variants on TCR/CD3-induced
lymphocyte responses as well as on their putative involvement in
autoimmunity by exploring their influence in SLE pathogenesis,
either as disease-susceptibility or as disease-modifier factor.
Materials and Methods
SLE genetic association study
The genetic study included a total of 681 samples from SLE
patients provided by different hospitals from Spain: Hospital
Virgen de las Nieves and Hospital Clı´nico San Cecilio, (Granada),
Hospital Carlos Haya (Ma´laga), Hospital Virgen del Rocı´o
(Sevilla), Hospital Parc Taulı´ (Sabadell), Hospital Xeral-Calde
(Lugo), and Hospital Central de Asturias (Oviedo), and 1,324
ethnically matched controls, all of them of European origin. All
patients fulfilled the American College of Rheumatology (ACR)
criteria for classification of SLE [36]. The demographic charac-
teristics of controls and clinical features of patients included in the
present study have been previously described [37]. SLE patients
were classified according to the presence or absence of nephritis
status. Lupus Nephritis (LN) is defined as clinical and laboratory
manifestations that meet ACR criteria (persistent proteinuria and/
or cellular casts including red blood cells [RBCs], hemoglobin,
granular, tubular, or mixed). Written informed consent was
obtained and the research followed the tenets of the Declaration of
Helsinki. The local Ethics Committees of the Hospital Clı´nico
Universitario San Cecilio (Granada, Spain), Hospital Virgen de las
Nieves (Granada, Spain), Hospital Marque´s de Valdecilla
(Santander, Spain), Hospital Parc Tauli (Sabadell, Spain), Hospital
Virgen del Rocı´o (Sevilla, Spain), Hospital Carlos Haya (Ma´laga,
Spain), Hospital Xeral-Calde (Lugo, Spain) and Hospital Central
de Asturias (Oviedo, Spain) approved the study.
The statistical analyses included association studies by 262
contingency tables and/or Fisher’s exact test when necessary. P-
values, OR and 95% CI were calculated using PLINK (V.1.07;
http://pngu.mgh.harvard.edu/purcell/plink/). Hardy–Weinberg
equilibrium (HWE) was tested for the studied SNPs at significance
level 0.01. Allelic combinations were constructed using Haploview
v4.2 by the implemented expectation–maximization algorithm. To
evaluate whether the allelic combinations would better explain the
possible association than the genetic variants independently, we
compared the goodness of fit of both models using PLINK.
Genotyping and SNP selection
Genomic DNA was extracted from EDTA-treated peripheral
blood samples following standard procedures (QIAsymphony SP
system, Qiagen). DNA samples were genotyped for the analyzed
SNPs rs2241002 (C/T, Pro224Leu) and rs2229177 (C/T,
Ala471Val) using predesigned TaqMan assays (Applied Biosys-
tems, Foster City, California, USA) with IDs: C_3237272_10 and
C_25472293_20. The linkage disequilibrium between the ana-
lyzed SNPs was D9= 0.16 and r2 = 0.01 in the control set.
T-cell proliferation assays and cytokine measurements
Peripheral blood mononuclear cells (PBMC) were obtained by
standard density gradient centrifugation over Ficoll (density
CD5 Polymorphism and SLE
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1.077 g/cm3; Linfosep, Biomedics) from EDTA-treated whole
blood of healthy volunteers all homozygous for Pro224 (C) at SNP
rs2241002 but being homozygous for either Ala471 (C) or Val471
(T) alleles at SNP rs2229177. Subjects gave informed consent
before blood samples were obtained.
Proliferation assays were conducted in triplicate in round
bottom 96-well plates (Costar, Corning NY, USA). PBMC (105)
were cultured for 72 h or 120 h at 37uC in a humidified
atmosphere of 5% CO2 in air in a final volume of 200 ml of X-
VIVO 15 (Lonza, Verviers, Belgium) in the absence or presence of
different concentrations (0.1, 1.0 and 10 ng/mL) of the mouse
monoclonal antibody (mAb) OKT3 (NC9983065, Ebioscience,
Hatfield, United Kingdom). [3H] thymidine (1 mCi/well; Mon-
avek Biochemicals, Bre, CA) was added for the last 16 h of the
culture period. Then the plates were centrifuged and the
supernatants collected and stored at 220uC for later determina-
tion of cytokine measurements. The cells were harvested using an
automatic cell harvester and the level of [3H] thymidine
incorporation determined in a Wallac 1205 Betaplate Liquid
Scintillation Counter. Results were presented as the mean 6
standard deviation (S.D.) of incorporated radioactivity, expressed
in counts per minute (c.p.m.). Statistical comparisons were
analyzed with two-tailed t Student test (confidence intervals of
95%) using GraphPad Prism version 4 for Windows (GraphPad
Software, San Diego, CA, USA).
Cytokine levels in cell culture supernatants were assessed by
using the Cytokine Human Ultrasensitive 10-Plex Panel
(LHC6004, Invitrogen, Camarillo, CA, USA). Results are
expressed in pg/mL as mean 6 S.D. Statistical analysis was
performed using a one-tailed Mann-Whitney test, with confidence
intervals (CI) of 95%.
Results
Peripheral blood T cells from homozygotes for the
Pro224-Ala471 CD5 haplotype are hyper-responsive to
TCR/CD3 cross-linking
Previous work has shown the existence of different signalling
capabilities among the Ala471Val variants of the CD5 molecule
when specifically cross-linked by either anti-CD5 mAb or the b-
glucan rich fungal particle zymosan [35]. Accordingly, the analysis
of either PBMC or cell transfectants, indicated that homozygous
carriers of the ancestral Pro240-Ala471 (CC) haplotype exhibit
lower intracellular signalling capability than those expressing the
more recently derived Pro240-Val471 (CT) variant. Based on
these results, as well as on the reported role of CD5 as negative
regulator of the antigen-specific receptor signalling, it was
hypothesized that expression of the Pro240-Ala471 haplotype
would result in lower attenuation of activation signals generated by
the T-cell receptor (TCR). To test this hypothesis, the lympho-
proliferative responses to TCR/CD3 cross-linking were measured
in PBMC from healthy individuals carrying the above mentioned
CD5 haplotypes. In order to reduce CD5 genetic variability and to
better ascertain the sole influence of the Ala471Val polymorphism
(which was the only one showing evidence for positive selection in
human populations) [35], only individuals homozygous for the
ancestral Pro224-Ala471 (CC, n = 4) or the more recently derived
Pro224-Val471 (CT, n = 5) haplotypes were compared. PBMC
from those individuals were then exposed to different concentra-
tions (0.1, 1.0 and 10 ng/mL) of the mouse anti-human CD3 mAb
OKT3 for different periods of time (72 h or 120 h) and their
proliferative capability measured by [3H] thymidine incorpora-
tion. As illustrated in Figure 1, T-cell proliferative responses at
72 h were significantly higher for Pro224-Ala471 (CC) homozy-
gotes (p = 0.024) only when high OKT3 doses (10 ng/mL) were
used. However, significant higher proliferative responses at all
OKT3 concentrations tested were observed in cultures terminated
at 120 h.
The influence of CD5 Ala471Val polymorphism at the gene
transcriptional level was also assessed by measuring cytokine
production in culture supernatants from individuals subjected to
TCR/CD3-induced T cell proliferation assays depicted in
Figure 1. In general, increased levels were observed in Pro224-
Ala471 homozygous (CC) individuals compared to Pro224-Val471
homozygous (CT) for most cytokines tested (Table 1). However,
the differences were either at the limit of statistical significance
(p = 0.057) or fully significant (p = 0.028) only for some of them
(GM-CSF, IFN-c, IL-2, IL-4, IL-5, IL-10 and TNF-a) and only at
certain time points (72 h and/or 120 h).
Taken together, the above-mentioned results indicate that
peripheral T cells from carriers of the ancestral and signalling-
defective CD5 Pro224-Ala471 haplotype are hyper-responsive to
TCR/CD3 cross-linking, compared to those carrying the more
recently derived Pro224-Val471 allele. This is in agreement with
the negative regulatory role assigned to CD5 in T cell activation
[30].
The ancestral CD5 Pro224-Ala471 haplotype associates
with SLE nephritis
Aberrant antigen receptor-mediated T-cell signalling and gene
transcription responses are commonly reported in SLE patients
[7]. Accordingly, an association study of the CD5 polymorphisms
was performed in a previously reported group of SLE patients [37]
and a group of controls both of Spanish origin. Genotyping success
rate was higher than 95% for both analyzed CD5 SNPs
(rs2241002 and rs2229177) and no statistically significant devia-
tion from Hardy-Weinberg equilibrium (P#0.01) was observed for
any of the CD5 SNPs studied in the control set. The genotypic and
allelic frequencies of the rs2241002 and rs2229177 CD5 SNPs in
the overall SLE patients, SLE patients stratified according to the
Figure 1. Influence of CD5 Ala471Val polymorphism on TCR/
CD3-induced peripheral T-lymphocyte proliferative responses.
PBMC (105 cells/well) from healthy blood donors homozygous for either
the Pro224-Ala471 (CC; n = 4) or the Pro224-Val471 (CT; n = 5)
haplotypes were cultured for 72 h or 120 h in the presence or absence
of 0.1, 1.0 or 10 ng/mL of anti-CD3 mAb OKT3. T-cell proliferation was
assessed by [3H] thymidine uptake and results expressed in c.p.m. as
mean 6 SD. Statistical analysis was performed by using two-tailed t
Student test with confidence intervals of 95%.
doi:10.1371/journal.pone.0113090.g001
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nephritis status as well as in controls are shown in Table 2 and 3.
No differences between SLE patients and control individuals
regarding the allelic and genotypic distribution of the analyzed
CD5 polymorphisms were observed. Nevertheless, when com-
pared the minor allele frequencies of both analyzed CD5
polymorphisms between SLE patients with presence of nephritis
and controls statistically significant results were detected for both
studied polymorphisms: rs2229177 p= 0.03 OR = 1.30 95%
CI(1.01–1.67); rs2241002 p= 0.02 OR = 0.68 95% CI (0.48–
0.96). On the other hand, the allelic combinations (haplotype)
frequencies conformed by the studied SNPs (rs2241002-
rs2229177) in overall SLE patients, SLE patients stratified
accordingly to nephritis status as well as in controls were also
analyzed and are shown in Table 4. A statistically significant
increase of the CD5 CC haplotype frequency in SLE nephritis
patients compared with controls group (p= 7.061024, OR = 1.52,
CI 95% = 1.18–1.95) was observed. Consistently, the haplotype
analysis according to the presence/absence of this clinical
condition reached statistical significance (p= 0.016, OR = 1.42,
CI 95% = 1.06–1.91). Additionally, when comparing haplotype
model with the independent SNP model, a statistically significant
improvement of the goodness of fit for the CC haplotype
compared to rs2229177 (likelihood p= 0.0089) or rs2241002
(likelihood p= 0.015) individually was observed.
Overall, these results support the notion that the ancestral
Pro224-Ala471 haplotype (CC) is associated with Lupus nephritis,
a common and severe complication of SLE. To perform a more
deeply analysis, we investigated whether the individuals carrying
two ancestral Pro224-Ala471 haplotype (CC) showed higher risk of
developing SLE nephritis compared with the rest of the
individuals. Thus, in the non CC-CC group we combined
individuals Leu224/Leu224-Val471/Val471 (TT-TT) and
Pro224/Leu224-Ala471/Val471 (CT-CT) since they did not show
differences and we did not take into account for the analysis
individuals carrying Leu224/Leu224-Ala471/Ala471 (TT-CC)
and Pro224/Pro224- Val471/Val471 (CC-TT) combinations in
order to avoid the influence of both polymorphisms separately on
the results. Interestingly, we observed a stronger risk effect when
we compared the Pro224-Ala471 homozygous individuals (CC-
CC) versus Non-Pro224/Pro224-Ala471/Ala471 (Non CC-CC)
frequencies between SLE with nephritis (SLE N+) and controls (P-
value = 3.21610-5 OR [95% CI] = 2.23 (1.49–3.33)) (Table 5).
Consistently, a statistically significant difference was also observed
when the same comparison was performed between SLE patients
with (SLE N+) and without (SLE N2) nephritis (P-val-
ue = 7.98610-3 OR [95% CI] = 1.88 (1.14–3.09)) while the
comparison between SLE patients without nephritis (SLE N2)
and controls did not reach significant results (P-value = 0.33).
Discussion
The present study provide the first evidence on the functional
relevance of CD5 polymorphisms in controlling the magnitude of
normal human T lymphocyte responses following antigen-specific
receptor triggering, as well as on their clinical relevance in
autoimmunity as a putative pathogenic factor for Lupus Nephritis
(LN). More precisely, it shows that peripheral T cells from healthy
volunteers carrying the ancestral CD5 Pro224-Ala471 haplotype
(CC) are hyper-responsive to TCR/CD3 cross-linking compared
to carriers of the more recently derived Pro224-Val471 haplotype
(CT), which was boosted by natural selection in East Asian
populations [35]. Moreover, the same ancestral haplotype by itself
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was insufficient to be associated with SLE susceptibility but with
predisposition to LN in a Spanish cohort of SLE patients and
controls. Therefore, this indicates that genetically determined
CD5-mediated lymphocyte hyper-reactivity may act as a disease-
modifier factor and result in clinical complications of SLE in
conjunction with other genetic and/or environmental factors.
Carriers of the CD5 Ala471 variant (rs2229177*C) have been
reported to be less efficient than Val471 ones (rs2229177*T) in
transducing early biochemical intracellular signals (namely,
MAPK cascade activation) when the CD5 receptor was cross-
linked via specific anti-CD5 mAbs or the b-glucan rich fungal
particle zymosan [35]. In the present work, the same Ala471
variant is found associated with higher overall TCR/CD3-induced
responses. This result fully fits with the negative regulatory
function assigned to CD5 in TCR-signal transduction, since
signalling-deficient CD5 variants (Ala471) would be expected to
lower the threshold for antigen-mediated activation resulting in
exacerbated T-cell proliferative responses. The fact that the
different regulatory potential of CD5 variants was evidenced
without the need of co-crosslinking of CD5 with TCR/CD3 is in
agreement with previous data showing that the ligation of the
extracellular domains of CD5 is meaningless to this regard [38].
One of the findings worth mentioning from the present study is
that two of the few cytokines giving statistically significant
differences at 120 h post-stimulation were IL-10 and IL-5, two
typical TH2 cytokines. SLE is considered a TH2-driven disease,
although elevation of both TH1 and TH2 cytokines occurs both in
human and mice, suggesting that it is a complex disease driven by
different lymphocyte subsets with high heterogeneity of clinical
manifestations and organ involvement [39]. Recent findings
regarding LN show an essential role of TH1 and TH17 cytokines
in the development of diffuse proliferative LN and of TH2 ones in
that of membranous LN [39]. The histopathological characteris-
tics of LN in our cohort are missing and it would deserve further
analysis in future studies.
Of note is also the fact that the hyper-reactivity of Pro224-
Ala471 haplotype (CC) carriers to TCR/CD3 cross-linking with
regard to Pro224-Val471 (CT) ones is reminiscent of the
phenotype reported for CD5-deficient mice [14,15]. CD5-
deficiencies have not been reported so far in human populations,
and the functional CD5 variants herein analyzed may represent
adaptation responses to different environmental pressures. In fact,
while the Pro224-Ala471 haplotype (CC) is well represented in
human populations of African descent, it is mostly absent from
East Asian populations where the more recently derived Pro224-
Val471 haplotype (CT) dominates [35]. These CD5 ethnic
differences could be relevant to the pathogenesis of SLE, whose
severity is known to vary among different ethnic groups. SLE has
been reported to be more prevalent and severe (including LN)
among African-American, Hispanic/Mestizo and Asian popula-
tion groups compared to their European counterparts [40,41].
Although the influence of lower socioeconomic status cannot be
ignored [42], it is tempting to speculate whether CD5 polymor-
phisms could be among the genetic factors influencing SLE ethnic
patterns, at least for individuals of African ancestry where the
hyper-reactive Pro224-Ala471 haplotype (CC) is prevalent.
The SLE missing heritability might be partially due to the great
clinical heterogeneity of the disease. LN is a challenging problem
that affects around 30–60% of SLE patients and a better
understanding of its aetiology is an important step in order to
identify and develop more targeted therapeutic approaches [43].
To date, no large-scale GWAS for SLE nephritis have been
published. Thus, consistent with the pre-GWAS era, the literature
on LN genetics has not attained the same level of maturity as it has
reached in SLE [44]. Very recently, the CD5 gene has been
identified as genetic risk factor associated with RA by a high
density genetic mapping approach [45]. Nowadays, it is well
established that multiple disease-associated genes are shared
between different autoimmune disorders [46,47]. For instance,
most of the genetic associations described for RA have been also
reported to play a role in the susceptibility to SLE [47]. Moreover,
preliminary results from our group indicates that CD5 polymor-
phism also influences the clinical expression of primary SS [48]
Considering the herein presented results and the previous findings
in RA and SS [45,48], the CD5 gene could be considered as a new
shared genetic risk or disease-modifier factor in autoimmunity.
Our data show that the rs2229177*C allele (Ala471) is related to
inherited lower inhibitory ability of both TCR-mediated signalling
and, consequently, a more increased lymphocyte proliferation. In
addition, the genetic study shows that the rs2229177*C allele
frequency is higher in the group of patients with SLE nephritis
than in those without this trait. It is important to note that it could
be suggesting that SLE patients carrying the rs2229177*C allele
could present more exacerbated lymphocyte responses and,
probably a more aggressive clinical outcome of the disease such
as LN. On the other hand, a significant additive effect was
Table 5. Frequency of combinations involving none, one and two Pro224-Ala471 haplotypes in overall SLE patients, SLE patients
stratified according to nephritis (N+, N2) status and controls.
Allelic combinations 1. SLE N+ 2. SLE N2 3. Controls n 2 vs 3P value 1 vs 3P value 1 vs 2P value
n (%) n (%) (%) OR [95% CI] OR [95% CI]
A) Leu224/Leu224 + Val471/Val471
(TT-CC)
34 (23.29) 80 (29.09) 389 (29.38) — — —
B) Pro224/Leu224 + Ala471/Val471
(CT-CT)
69 (47.26) 145 (52.73) 726 (54.83) — — —
A+B) non CC-CC 103 (70.55) 225 (81.82) 1115 (84.21) — — —
C) Pro224/Pro224 -Ala471/Ala471
(CC-CC)
43 (29.45) 50 (18.18) 209 (15.79) 0.33 3.216105 2.2
(1.49–3.33)
7.98610231.9 (1.14–3.09)
P-values were obtained by comparing the frequencies of Pro224-Ala471 homozygous individuals (group C) and the frequencies of Non-Pro224/Pro224 -Ala471/Ala471
individuals (groups A+B) within the different subgroups of patients and controls.
doi:10.1371/journal.pone.0113090.t005
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observed between the selected polymorphisms because the most
associated allelic combination with SLE nephritis was that
containing the risk alleles (the CC haplotype) of the two studied
SNPs. Thus, both genetic alterations together, caused by these risk
alleles, could be of higher relevance than only one of these in the
pathogenic mechanisms that lead to SLE nephritis. Nevertheless,
further studies using dense mapping are required in order to
investigate whether the associated allelic combination is the
causative genetic risk factor or otherwise is in strong linkage
disequilibrium with the real causal variant/s, as well as to be able
to rule out the potential contribution of other genetic factors
located within this region.
In conclusion, the functional data herein reported reinforce the
notion of CD5 being an important modulatory molecule in T cell
activation and support a role for the CD5 gene polymorphisms in
modifying the phenotypical characteristics of SLE patients, thus
suggesting that CD5 might represent a potential target for future
therapeutic intervention of this autoimmune condition.
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